Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session: NETs and endocrine tumours

1MO - An open-label, phase II trial of cabozantinib for advanced adrenocortical carcinoma

Date

12 Sep 2022

Session

Mini Oral session: NETs and endocrine tumours

Topics

Tumour Site

Adrenal Carcinoma

Presenters

Matthew Campbell

Citation

Annals of Oncology (2022) 33 (suppl_7): S1-S3. 10.1016/annonc/annonc

Authors

M.T. Campbell1, C. Jimenez2, J.P. Long3, J. Varghese4, A. Shah5, M. Zhang6, G. Tamsen4, M.A. Habra4

Author affiliations

  • 1 Genitourinary Medical Oncology, The M. D. Anderson Cancer Center, 77030 - Houston/US
  • 2 Endocrine Neoplasia And Hd, Banner MD Anderson Cancer Center, 85234 - Gilbert/US
  • 3 Biostatistics, The University of Texas M. D. Anderson Cancer Center, 77030 - Houston/US
  • 4 Endocrine Neoplasia And Hd, The University of Texas M. D. Anderson Cancer Center, 77030 - Houston/US
  • 5 Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 77030 - Houston/US
  • 6 Pathology, Anatomical, MD Anderson Cancer Center, 77030 - Houston/US
More

Resources

Login to access the resources on OncologyPRO.

Abstract 1MO

Background

Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with limited treatment options. This study aims to explore the role of carbozantinib in ACC management.

Methods

This is an investigator initiated, phase II study to evaluate the efficacy and safety of cabozantinib in patients with advanced ACC. Response to therapy was assessed objectively using The Response Evaluation Criteria in Solid Tumors (RECIST)v1.1. The primary end point was progression free survival (PFS) at 4 months (mo) (PFS4). Secondary endpoints included median PFS, overall response rate (ORR), median overall survival (OS), pharmacokinetic studies, and safety. Correlative tissue-based studies were performed.

Results

The study has fully accrued enrolling 18 patients with advanced ACC (8 females (44%). The median follow-up was 19.4 mo (range 2.9-45.6). The PFS4 was 72% (13/18), median PFS was 7.2 mo (95%CI: 3.3,9.2 mo). Of 18 patients, 16 had restaging with ORR including 2 partial response, 12 stable disease, and 2 progressive disease as best response; disease control rate was 78% (95% CI, 52% to 94%). The median PFS was 7.2 mo (95% CI, 3.3 mo to 9.2 mo), and the median OS was 23.9 mo (95% CI, 12.9, not reached). 13 patients (72.2%) had at least possible treatment-related grade 3 or 4 adverse events. Median day 29 pre-dose level of cabozantinib was 505mg/mL (range 279-1810). Correlative study analysis will be presented.

Conclusions

Cabozantinib use in patients with advanced ACC can provide sustained disease control with manageable safety profile in the majority of ACC patients.

Clinical trial identification

NCT03370718.

Editorial acknowledgement

Legal entity responsible for the study

University of Texas MD Anderson Cancer Center.

Funding

Exelixis.

Disclosure

M.T. Campbell: Financial Interests, Personal, Research Grant: Exelixis. C. Jimenez: Non-Financial Interests, Personal, Other, Research Support: Exelixis; Non-Financial Interests, Personal, Advisory Board: Merck Sharp & Dohme, Progenics, Lantheus, Pfizer, HRA Pharma. A. Shah: Non-Financial Interests, Personal, Advisory Board: Pfizer, Exelixis, BMS; Non-Financial Interests, Personal, Other, Research Support: 4D Pharma, Eisai, EMD Serono. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.